<unk>  varieties have been explored extensively as a viral vector for gene therapy and also as an<unk>  virus. Of the many different viruses being explored for<unk>  potential, an<unk>  was the first to be approved by a regulatory agency, the genetically modified H101 strain. It gained regulatory approval in 2005 from China's State Food and Drug Administration (SFDA) for the treatment of head and neck cancer.
Oncolytic adenovirus
Prospect Hill orthohantavirus
Passenger virus
Seoul orthohantavirus
Sin Nombre orthohantavirus
Argentinian mammarenavirus
Flexal mammarenavirus
Dobrava-Belgrade orthohantavirus